Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover
Apogee Therapeutics soared 47% to $132.69 after AbbVie agreed to acquire it for $135.11 per share in cash, adding late-stage eczema drug zumilokibart to its pipeline; shares remain 1.8% below the offer as investors weigh approval, antitrust, and shareholder risks, with the deal expected to close in Q3 2026.